Focus: NorthStar Medical Technologies is a Wisconsin-based biotech company specializing in medical radioisotopes for diagnostic imaging across neurology, cardiovascular, and oncology indications. The company operates a portfolio of generic and branded radiopharmaceutical products with limited public-market scale indicators.
Profile data last refreshed 20h ago · AI intelligence enriched 3w ago
Hot — 45 jobs added in 30d
Net +34 (45 new, 11 removed). Aggressive expansion phase.
Best suited for manufacturing, quality, and operations professionals seeking stable, specialized roles in radiopharmaceuticals; risky for R&D, clinical, or commercial professionals seeking long-term innovation career growth.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generates 100% of company revenue; extreme concentration risk for a post-LOE generic with minimal Part D spending.
Help build intelligence for NorthStar Medical Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NorthStar Medical Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Post-LOE beta-blocker in mature market; no recorded Part D spending indicates minimal revenue contribution.
Post-LOE GABA agonist; no Part D revenue recorded, suggesting limited commercial scale.
Post-LOE beta-blocker for multiple indications; no Part D revenue indicates minimal current contribution.
Post-LOE antiemetic; no recorded Part D spending suggests minimal revenue impact.
Post-LOE xanthine oxidase inhibitor; no Part D revenue recorded.
NDA-approved radiopharmaceutical device at peak lifecycle; core proprietary asset and differentiator in company's radioisotope specialty.
Post-LOE opioid analgesic; no Part D revenue recorded, suggesting minimal portfolio contribution.
7 discontinued, 3 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo